Browse the evidence

Berberine (BBR) shows multi-target anti-obesity actions in preclinical models (AMPK activation, gut microbiota modulation) but suffers from poor oral bioavailability (<5%) and lacks sufficient clinical validation for obesity.

Berberine is a natural compound with preclinical evidence for weight loss, but it has very low absorption in the body (<5%) and hasn't been proven effective in large clinical trials for obesity. While safe for other uses, it is not yet a recommended treatment for weight loss.

Flavonoids inhibit glucose transporters (GLUT2, GLUT5, GLUT7), thereby reducing intestinal glucose and fructose absorption.

Eating flavonoid-rich foods might slightly slow down sugar absorption by affecting transporters in the gut. This is a subtle effect and should not replace a balanced diet, but it may offer some metabolic benefit.

GLP-1 receptor agonists (specifically liraglutide and exendin-4) inhibit cancer progression and proliferation in various malignancies (breast, prostate, pancreatic, ovarian, colon, liver) through mechanisms including apoptosis induction, cell cycle arrest, and inhibition of signaling pathways like PI3K/Akt/mTOR and MAPK.

This paper highlights that while semaglutide (Ozempic/Wegovy) has mixed signals regarding cancer risk in humans, other GLP-1 agonists like liraglutide and exendin-4 have demonstrated anti-cancer effects in laboratory and animal studies. For patients, this underscores the importance of discussing specific drug risks with a doctor, especially those with a history of cancer, as the effect is not uniform across all drugs in this class.

The appetite-suppressing effects of GLP-1 analogs attenuate during the weight maintenance phase, suggesting that the biological drive to lose weight diminishes once a new homeostatic fat mass is reached.

As you reach your target weight, the strong appetite suppression from GLP-1 medications may lessen. This is a normal physiological response as your body adjusts to its new weight. Continued monitoring and potentially lifestyle adjustments may be needed to maintain weight loss.

UPF intake may influence energy intake and metabolic responses through factors like energy density, eating rate, and hyper-palatability, but these mechanisms are not yet fully understood.

Try to be mindful of how quickly you eat and the energy density of your meals. UPFs are often designed to be hyper-palatable and energy-dense, which can lead to overconsumption. Choosing whole, minimally processed foods may help regulate energy intake.

Vegetarian diets do not significantly reduce the risk of gestational diabetes or hypertension in pregnant women compared to omnivorous diets.

If you are pregnant, switching to a vegetarian diet may not specifically reduce your risk of gestational diabetes or high blood pressure compared to a standard diet. Consult your doctor for personalized advice.

For Semaglutide, higher doses are associated with a higher risk of intolerable gastrointestinal adverse reactions.

If you are taking Semaglutide and experiencing intolerable gastrointestinal side effects, discuss with your doctor whether a lower dose (e.g., 0.5mg) might be sufficient to manage your condition with fewer side effects, as higher doses (1mg) are associated with a higher risk of these reactions.

The protective association between plant-based diets and weight loss is weaker or absent in individuals with existing obesity compared to those with normal or overweight status.

If you have obesity, you may find weight loss more challenging with plant-based diets due to metabolic factors like insulin resistance. However, focusing on healthful plant foods remains important for overall health and may still support weight management, even if the effect is less pronounced than in non-obese individuals.

Repeated application of cooling does not affect endurance training adaptations following 4–6 week training interventions.

If you are training for endurance, you can use cold water immersion without worrying about it hurting your long-term aerobic gains. It won't help them either, so use it based on comfort or early recovery needs, not for chronic adaptation.

GLP-1 receptor agonists are associated with a rapid worsening of diabetic retinopathy, particularly in patients with a history of retinopathy and those using insulin, likely due to rapid glycemic improvement.

If you have diabetes and are starting a GLP-1 medication, ensure you have regular eye exams. If you already have eye problems, your doctor may monitor you more closely, as rapid blood sugar improvement can temporarily worsen vision.

GLP-1RA users tend to overconsume saturated fat and total fat percentages, potentially exacerbating gastrointestinal side effects like nausea and constipation.

You are likely eating too much saturated fat, which can worsen nausea and constipation common with GLP-1RA. Try to shift some calories from fats to fiber-rich carbohydrates and protein to improve GI comfort and nutrient density.

A higher polygenic score for BMI is associated with lower weight loss following bariatric surgery, although the effect size is modest and attenuates in sensitivity analyses.

If you are considering bariatric surgery, having a high genetic risk for obesity might mean you lose slightly less weight than someone with low genetic risk. However, the surgery is still very effective. You may need to be more vigilant with lifestyle changes or consider adjunct therapies like GLP-1 RAs to maintain your results.

Obese gut microbial communities exhibit higher branched-chain amino acid (BCAA) catabolism and hexanoic acid production, which may negatively impact energy balance and metabolic health.

Obese gut bacteria may metabolize proteins differently, producing metabolites like hexanoic acid that could affect energy balance. This highlights why metabolic health in obesity is complex and not just about calorie intake.

Inhibitors of hepatic lipogenesis (including ACLY, ACC, FAS, SCD1, and DGAT2 inhibitors) reduce liver fat content in MASLD, but some (like ACC inhibitors) may increase serum triglycerides, necessitating combination therapies (e.g., ACC + DGAT2 inhibitors) to mitigate adverse lipid effects.

Several new drugs target the liver's fat-making enzymes (like ACC and FAS). While they reduce liver fat, some can raise blood triglycerides. To avoid this, doctors may combine an ACC inhibitor with a DGAT2 inhibitor. These are still largely in clinical trials and are not yet first-line treatments compared to GLP-1 agonists.

In healthy adults, higher dietary saturated fat intake is independently associated with higher LDL-C, but this relationship is not dose-dependent across typical intake ranges and is largely explained by abdominal visceral adipose tissue (VAT) mass rather than the fat itself.

If you are healthy and have a normal BMI, simply reducing saturated fat might not significantly lower your LDL-C if you have high visceral fat. Focus on overall body composition and visceral fat reduction, as these factors appear to drive LDL-C levels more strongly than SFA intake alone in this population.

SGLT2 inhibitors reduce hepatic lipid content and liver enzymes in patients with MASLD and Type 2 Diabetes, but histological evidence for treating MASH is still required.

If you have diabetes and fatty liver, SGLT2 inhibitors (like dapagliflozin) are a good option to lower liver fat and enzymes. They work by changing how your body handles sugar and fat. However, they are not yet proven to reverse the scarring of MASH, so they are part of a broader management strategy.

The peptide triple agonist GEP44, targeting GLP-1, Y1, and Y2 receptors, promotes profound weight loss and glycemic control in diet-induced obese rats without triggering the nausea or malaise associated with standard GLP-1 receptor agonists.

This research highlights a promising new class of drugs (triple agonists like GEP44) that may offer superior weight loss and blood sugar control compared to current GLP-1 medications, without causing the nausea that often stops people from taking them. However, this is currently only proven in animals, not humans. For now, standard GLP-1s remain the primary option, but patients experiencing intolerable side effects might discuss clinical trials or future availability of these multi-agonists with their healthcare provider.

Meal timing is not associated with body composition (fat mass, lean mass, or BMI) in young adults, regardless of sex.

Changing when you eat will not directly change your weight or body fat percentage. Focus on total calorie intake and exercise for body composition changes. However, timing may still be useful for metabolic health markers like insulin sensitivity.

GLP-1RAs activate neurons in the paraventricular nucleus (PVH) and ventromedial hypothalamus (VMH) to suppress food intake and increase energy expenditure or thermogenesis.

GLP-1 medications also target other brain regions (PVH and VMH) to suppress food intake and increase energy expenditure. This helps explain why these medications can lead to weight loss even without significant changes in diet or exercise.

Continuing lifestyle interventions (diet/exercise) after stopping AOMs does not prevent significant weight regain, as this subgroup also showed significant regain.

Even if you maintain a healthy diet and exercise routine, stopping anti-obesity medication is likely to lead to weight regain. The biological effects of the medication are significant, and lifestyle changes alone may not be enough to counteract the regain.

Relying solely on Fasting Plasma Glucose (FPG) for diagnosis misses a significant number of diabetes cases in Korean populations; OGTT or HbA1c is required for accurate diagnosis.

If you are Asian or have a lower body weight, a normal fasting blood sugar might not mean you are safe. You may have high blood sugar after eating. Ask your doctor about an OGTT or HbA1c test if you have risk factors.

HbA1c is a valid diagnostic criterion for diabetes (≥6.5%) in Korea, but it should not be used alone due to lower detection rates compared to combined FPG and OGTT.

HbA1c is a convenient test that doesn't require fasting, but it might miss diabetes if used alone. For the most accurate diagnosis, especially if you have conditions like anemia or kidney disease, combine it with fasting glucose or an OGTT.

Macrophage-specific lipoprotein lipase (LPL) promotes atherosclerosis by acting as a bridging molecule for remnant lipoprotein uptake, leading to foam cell formation and plaque progression.

LPL helps clear fat from blood, but in immune cells within artery walls, it helps build plaques. Therapies targeting LPL must distinguish between clearing blood fat (good) and feeding artery plaques (bad).

Dispensing rates for GLP-1 RAs are significantly lower for obesity (AOM) indications compared to diabetes (ADM) indications, with a large gap in 60-day initiation rates.

Even if prescribed, GLP-1 RAs for weight loss are less likely to be filled than those for diabetes, largely due to insurance coverage issues. If you are prescribed an AOM GLP-1 RA, proactively check your insurance coverage and explore assistance programs to ensure you can access the medication.